A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Apr 20, 2006

Approval for Candin Antifungal Agent Funguard for Pediatrics in Japan

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that the candin antifungal agent, "Funguard® for Infusion" (generic name: micafungin...

Read more about Approval for Candin Antifungal Agent Funguard for Pediatrics in Japan
Apr 17, 2006

Consideration of the sale of Zepharma shares has been fixed

Tokyo, Japan April 17, 2006 - Astellas Pharma Inc. (President and CEO: Toichi Takenaka, "Astellas") today announced that the total consideration for the sale of all outstanding shares of Zepharma...

Read more about Consideration of the sale of Zepharma shares has been fixed
Apr 13, 2006

MAA Submission for Candin Antifungal Agent Micafungin in EU

Japan, April 13, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that its EU subsidiary submitted a Marketing Authorization...

Read more about MAA Submission for Candin Antifungal Agent Micafungin in EU
Apr 3, 2006

Astellas Establishes New Subsidiary "Astellas Pharma Chemicals Co., Ltd."

Astellas Pharma Inc.("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing...

Read more about Astellas Establishes New Subsidiary "Astellas Pharma Chemicals Co., Ltd."
Apr 3, 2006

Astellas to Acquire AMEVIVE (alefacept) (pdf 28KB)

Read more about Astellas to Acquire AMEVIVE (alefacept) (pdf 28KB)
Mar 31, 2006

Basic Licensing Agreement Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 24KB)

Read more about Basic Licensing Agreement Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 24KB)
Mar 31, 2006

Astellas Sells All Outstanding Shares of Its OTC Business Subsidiary, Zepharma Inc., to Daiichi Sankyo Co., Ltd. (pdf 13KB)

Read more about Astellas Sells All Outstanding Shares of Its OTC Business Subsidiary, Zepharma Inc., to Daiichi Sankyo Co., Ltd. (pdf 13KB)
Mar 31, 2006

Astellas Issues a Statement on Today's Nikkei News (pdf 8KB)

Read more about Astellas Issues a Statement on Today's Nikkei News (pdf 8KB)
Mar 31, 2006

Astellas Receives FDA Approval of Prograf (Tacrolimus) for Use in Heart Transplant Recipients (pdf 52KB)

Read more about Astellas Receives FDA Approval of Prograf (Tacrolimus) for Use in Heart Transplant Recipients (pdf 52KB)
Mar 23, 2006

Licensing Agreement for the Development, Manufacturing and Marketing of Anti-human Osteopontin Antibodies (pdf 10KB)

Read more about Licensing Agreement for the Development, Manufacturing and Marketing of Anti-human Osteopontin Antibodies (pdf 10KB)
Mar 9, 2006

Announcement of an Early Retirement Program Following the Transfer of Business Functions at Doshomachi Office

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has decided to offer an early retirement program for its employees at its Doshomachi office and employees...

Read more about Announcement of an Early Retirement Program Following the Transfer of Business Functions at Doshomachi Office
Mar 1, 2006

Dynogen Research Operation Acquired by Astellas Pharma Inc. (pdf 24KB)

Read more about Dynogen Research Operation Acquired by Astellas Pharma Inc. (pdf 24KB)
Feb 27, 2006

Astellas to Delist Shares from Three Stock Exchanges

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) decided at a board meeting held today that it will apply for delisting of its common stocks from the...

Read more about Astellas to Delist Shares from Three Stock Exchanges
Feb 9, 2006

Astellas Issues a Statement on Today's Asahi News

Japan, February 9, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced a following statement with regard to the news appeared on the...

Read more about Astellas Issues a Statement on Today's Asahi News
Jan 31, 2006

Recent Progress in the New Drug Development

Japan, January 31, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that it has recently achieved the following progress in its...

Read more about Recent Progress in the New Drug Development
Jan 31, 2006

Ferring and Astellas Enter a License Agreement on Degarelix for the Treatment of Prostate Cancer in Japan (pdf 22KB)

Read more about Ferring and Astellas Enter a License Agreement on Degarelix for the Treatment of Prostate Cancer in Japan (pdf 22KB)
Jan 27, 2006

SNDA for a Fast-Acting Postprandial Hypoglicemic Agent FASTIC Tablet / STARSIS Tablet for Combinaition Therapy with Biguanide was Filed (pdf 11KB)

Read more about SNDA for a Fast-Acting Postprandial Hypoglicemic Agent FASTIC Tablet / STARSIS Tablet for Combinaition Therapy with Biguanide was Filed (pdf 11KB)
Jan 27, 2006

Astellas Has Established Astellas Venture Management in the US

Japan, January 27, 2006 - Astellas Pharma Inc. (headquarters: Tokyo; president and CEO: Toichi Takenaka; hereafter "Astellas") today announced that it has established Astellas Venture Management...

Read more about Astellas Has Established Astellas Venture Management in the US
Jan 26, 2006

Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 23KB)

Read more about Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 23KB)
Dec 30, 2005

FDA Approves Astellas' VAPRISOL for the Treatment of Euvolemic Hyponatremia (pdf 74KB)

Read more about FDA Approves Astellas' VAPRISOL for the Treatment of Euvolemic Hyponatremia (pdf 74KB)
Dec 26, 2005

NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US

Astellas Pharma US, Inc. (headquarters: Deerfield, Illinois; Chairman and CEO: Makoto Nishimura), a US subsidiary of Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO:...

Read more about NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US
Dec 21, 2005

Study design and patient background of a large-scale clinical study, INNOVATION, of the angiotensin II receptor blocker MICARDIS was published in medical journal (pdf 2.7MB)

Read more about Study design and patient background of a large-scale clinical study, INNOVATION, of the angiotensin II receptor blocker MICARDIS was published in medical journal (pdf 2.7MB)
Dec 16, 2005

CO-Promotion Agreement between Astellas and sanofi-aventis Group Japan for Hypnotic Myslee (zolpidem tartrate) (pdf 11KB)

Read more about CO-Promotion Agreement between Astellas and sanofi-aventis Group Japan for Hypnotic Myslee (zolpidem tartrate) (pdf 11KB)
Dec 16, 2005

Astellas Transfers Its Group Member Company FMS Co., Ltd. to Canon System Solutions Inc. of the Canon Sales Group (pdf 11KB)

Read more about Astellas Transfers Its Group Member Company FMS Co., Ltd. to Canon System Solutions Inc. of the Canon Sales Group (pdf 11KB)
Dec 9, 2005

Purchase of the Company's Own Shares in the Market (pdf 8KB)

Read more about Purchase of the Company's Own Shares in the Market (pdf 8KB)
Nov 30, 2005

XenoPort and Astellas Enter a License Agreement on XP13512 in Japan and Five Asian Countries (pdf 36KB)

Read more about XenoPort and Astellas Enter a License Agreement on XP13512 in Japan and Five Asian Countries (pdf 36KB)
Nov 29, 2005

Astellas Sues Toyo Pharmar and Aska Pharmaceutical for Infringement of Patent on Harnal Capsule

Japan, November 29, 2005 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Astellas filed a patent infringement lawsuit on November...

Read more about Astellas Sues Toyo Pharmar and Aska Pharmaceutical for Infringement of Patent on Harnal Capsule
Nov 7, 2005

Astellas Revises Its Dividends Forecasts for Current Fiscal Year (pdf 12KB)

Read more about Astellas Revises Its Dividends Forecasts for Current Fiscal Year (pdf 12KB)
Nov 7, 2005

Notice Regarding Acquisition of the Company's Own Shares (pdf 9KB)

Read more about Notice Regarding Acquisition of the Company's Own Shares (pdf 9KB)
Nov 7, 2005

Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections (pdf 25KB)

Read more about Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections (pdf 25KB)
Nov 2, 2005

Collaborative Search for Microorganisms in Vietnam (pdf 15KB)

Read more about Collaborative Search for Microorganisms in Vietnam (pdf 15KB)
Oct 28, 2005

Astellas Announces Dissolution of Astellas Systems (pdf 44KB)

Read more about Astellas Announces Dissolution of Astellas Systems (pdf 44KB)
Oct 26, 2005

Revision of the Interim and Full Year Business Forecasts for FY2005 (pdf 24KB)

Read more about Revision of the Interim and Full Year Business Forecasts for FY2005 (pdf 24KB)
Oct 21, 2005

Invention Encouragement Prize of the FY2005 Kanto Local Commendation for Invention Was Awarded to Astellas' fast-disintegrating Tablet Technology WOWTAB-DRY

Japan, October 21, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that the fast-disintegrating tablet technology "

Read more about Invention Encouragement Prize of the FY2005 Kanto Local Commendation for Invention Was Awarded to Astellas' fast-disintegrating Tablet Technology WOWTAB-DRY
Oct 12, 2005

Luvox® Receives Approval for Social Anxiety Disorder as an Additional Indication

Japan, October 12, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that the antidepressant "Luvox® Tablet"...

Read more about Luvox® Receives Approval for Social Anxiety Disorder as an Additional Indication
Oct 12, 2005

Astellas to Support the Relief Effort Following Earthquake Struck in Northern Pakistan

Japan, October 12, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that Astellas will make a donation of...

Read more about Astellas to Support the Relief Effort Following Earthquake Struck in Northern Pakistan
Oct 4, 2005

Astellas and MerLion Pharmaceuticals announce new drug discovery agreement (pdf 33KB)

Read more about Astellas and MerLion Pharmaceuticals announce new drug discovery agreement (pdf 33KB)
Sep 15, 2005

Astellas Filed Lawsuit against Taiyo Yakuhin Co., Ltd. for Infringement of Patent on the Oral Cephalosporin Antibiotic Cefzon Capsule

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) filed a patent infringement lawsuit on September 15 with the Tokyo District court against Taiyo Yakuhin...

Read more about Astellas Filed Lawsuit against Taiyo Yakuhin Co., Ltd. for Infringement of Patent on the Oral Cephalosporin Antibiotic Cefzon Capsule
Sep 5, 2005

Astellas to Support the Relief Effort Following Hurricane Katrina Hit in the US

Japan, September 5, 2005 - Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as "Astellas") today announced that the Astellas Group will make a...

Read more about Astellas to Support the Relief Effort Following Hurricane Katrina Hit in the US
Sep 1, 2005

Purchase of the Company's Own Shares in the Market (pdf 8KB)

Read more about Purchase of the Company's Own Shares in the Market (pdf 8KB)
Sep 1, 2005

Transfer of Almatol tablets and HelmitinS suppositories to Choseido (pdf 11KB)

Read more about Transfer of Almatol tablets and HelmitinS suppositories to Choseido (pdf 11KB)
Aug 24, 2005

Allotment of Stock Acquisition Rights as Stock Option Scheme for Stock-Linked Compensation Plan (pdf 12KB)

Read more about Allotment of Stock Acquisition Rights as Stock Option Scheme for Stock-Linked Compensation Plan (pdf 12KB)
Aug 24, 2005

Finalized Plan for Separation of the API Production at Takahagi Site (pdf 34KB)

Read more about Finalized Plan for Separation of the API Production at Takahagi Site (pdf 34KB)
Aug 11, 2005

Astellas Will Implement Early Retirement Programs at Its Domestic Subsidiaries (pdf 9KB)

Read more about Astellas Will Implement Early Retirement Programs at Its Domestic Subsidiaries (pdf 9KB)
Aug 2, 2005

Notice Regarding Acquisition of the Company's Own Shares (pdf 16KB)

Read more about Notice Regarding Acquisition of the Company's Own Shares (pdf 16KB)
Jul 18, 2005

International Symposium on "Telmisartan(MICARDIS)" (pdf 156KB)

Read more about International Symposium on "Telmisartan(MICARDIS)" (pdf 156KB)
Jul 6, 2005

Astellas has ended the agreement regarding "AczoneTM" in North America

Japan, July 6, 2005 - Astellas Pharma Inc. today announced that Astellas US LLC, its wholly owned subsidiary headquartered in Deerfield, IL.(Chairman and CEO; Makoto Nishimura, Ph.D.) has executed...

Read more about Astellas has ended the agreement regarding "AczoneTM" in North America
Jun 24, 2005

Separation of the API Production at Takahagi Site

Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) decided at a board meeting held on June 24 to integrate its active pharmaceutical ingredient (API)...

Read more about Separation of the API Production at Takahagi Site
Jun 10, 2005

The Orally Disintegrating Tablet "Harnal® D Tablet" for the Treatment of Functional Symptoms of Benign Prostatic Hyperplasia to be Available in Japan

Japan, June 10, 2005 - Astellas Pharma Inc. ("Astellas") today announced that a new dosage form of Harnal® (generic name: tamsulosin HCl), the orally disintegrating tablet "Harnal® D Tablet...

Read more about The Orally Disintegrating Tablet "Harnal® D Tablet" for the Treatment of Functional Symptoms of Benign Prostatic Hyperplasia to be Available in Japan
May 27, 2005

Astellas US LLC and Astellas Pharma US, Inc. Filed Lawsuit against Adenoscan Generic for Patent Infringement in the USA

Astellas and King File Lawsuit against Adenoscan® Generic for Patent Infringment in the USA

Deerfield, Ill., May 26, 2005- King Pharmaceuticals Research and Development, Inc. ("King") along with Astellas US LLC and Astellas Pharma US, Inc. ("Astellas") announced today that they have...

Read more about Astellas US LLC and Astellas Pharma US, Inc. Filed Lawsuit against Adenoscan Generic for Patent Infringement in the USA
May 17, 2005

Issuance of Stock Acquisition Rights as Stock Option Scheme for Stock-Linked Compensation Plan (pdf 15KB)

Read more about Issuance of Stock Acquisition Rights as Stock Option Scheme for Stock-Linked Compensation Plan (pdf 15KB)
May 17, 2005

Astellas will Dissolve its Subsidiary for Home Care business

Japan, May 17, 2005 - Astellas Pharmaceutical Co., Ltd.(Astellas) today announced that Astellas has decided a dissolution of Astellas Medical Care Co., Ltd., its wholly owned subsidiary engaged in...

Read more about Astellas will Dissolve its Subsidiary for Home Care business
May 16, 2005

Astellas will Withdraw from its Medical Supplies and Systems Business

Japan, May 16, 2005 - Astellas Pharma Inc. (Astellas) today announced its decision to withdraw from its Medical Supplies and Systems Business along with the corporate strategy to concentrate on...

Read more about Astellas will Withdraw from its Medical Supplies and Systems Business
May 16, 2005

Astellas and Boehringer Filed Lawsuit against FLOMAX® Generic for Patent Infringement in the USA

Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Toichi Takenaka; "Astellas") and Boehringer Ingelheim Pharmaceuticals, Inc. ("BIPI"), a US subsidiary of Boehringer Ingelheim of...

Read more about Astellas and Boehringer Filed Lawsuit against FLOMAX® Generic for Patent Infringement in the USA
May 13, 2005

Anti-fungal Agent MYCAMINETM Available to Physicians

--First Astellas Product Launched in the United States--

Deerfield, IL, -- May 13, 2005, Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent MYCAMINETM (micafungin sodium) for Injection to...

Read more about Anti-fungal Agent MYCAMINETM Available to Physicians
Apr 11, 2005

Prograf ® Is Approved For Additional Indication of Rheumatoid Arthritis

Japan, April 11, 2005 - Astellas Pharma Inc. ("Astellas") today announced that the Company obtained an approval from the Ministry of Health, Labor and Welfare (MHLW) for the immunosuppressant...

Read more about Prograf ® Is Approved For Additional Indication of Rheumatoid Arthritis
Apr 1, 2005

Astellas Pharma Start Today As A New Star in the World Pharmaceutical Industry

April 1st, 2005 Astellas Pharma Inc. ("Astellas"), today announced that the Company, headquartered in Tokyo, Japan, was created through the merger of Yamanouchi Pharmaceutical Co., Ltd....

Read more about Astellas Pharma Start Today As A New Star in the World Pharmaceutical Industry
Mar 18, 2005

Astellas Pharma Inc.Appoints Representative Directors and Corporate Officers (pdf 47KB)

Read more about Astellas Pharma Inc.Appoints Representative Directors and Corporate Officers (pdf 47KB)
Mar 17, 2005

Astellas Pharma Inc.Appoints Representative Directors and Corporate Officers (pdf 47KB)

Read more about Astellas Pharma Inc.Appoints Representative Directors and Corporate Officers (pdf 47KB)

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts